Characteristics of HBeAg-positive patients chronically infectedwith hepatitis b virus (HBV) who achieved hbsag loss/seroconversion following tenofovir disoproxil fumarate (TDF) tr…
J Petersen, M Manns, S Mauss, S Zeuzem, G Teuber, B Möller, J Heathcote, P Marcellin, J Sorbel, F Rousseau · Zeitschrift für Gastroenterologie · 2009 · Heft 09
Bibliografische Angaben
Zusammenfassung
Aims: HBsAg loss was observed in significantly more TDF-treated patients versus adefovir dipivoxil (ADV) at Week (W) 48 in HBeAg-positive patients enrolled in the pivotal, phase 3 study 103 (3.2% TDF versus 0% ADV; p=0.02). Goal: To characterize the TDF-treated patients who achieved HBsAg loss by W96 in study 103. Methods: Patients with HBeAg-positive chronic hepatitis B (CHB) were randomized to double-blind, once daily TDF 300mg (N=176) or adefovir dipivoxil 10mg (ADV) (N=90). After W48, eligible patients (with a W48 liver biopsy) initiated open-label TDF for an additional 7 years. Two year data are presented.…
